secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001104659-25-107438
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune reports Q2 net loss $83.1M; FDA accepts RP1 BLA resubmission with PDUFA April 10, 2026
--------------------------------------------------------------------------------

- Cash, equivalents and investments $323.6M at Sep 30, 2025, down from $483.8M at Mar 31, 2025.
- R&D expenses $57.9M vs $43.4M YoY; S,G&A $26.4M vs $15.5M YoY.
- Net loss $83.1M vs $53.1M in prior year quarter.
- FDA accepted BLA resubmission for RP1 in advanced melanoma; PDUFA target action date April 10, 2026.
- Phase 3 IGNYTE-3 trial enrolling ~400 patients; REVEAL Phase 2/3 for RP2 in uveal melanoma enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/0001104659-25-107438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465925107438/tm2530417d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-107438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer